BR112018068877A2 - sal de citrato do composto de ácido (s)-4-((s)-3-fluoro-3-(2-(5,6,7,8-tetraidro-1,8-naftiridin-2-il)etil)pirrolidin-1-il)-3-(3-(2-metoxietoxi) fenil) butanoico - Google Patents

sal de citrato do composto de ácido (s)-4-((s)-3-fluoro-3-(2-(5,6,7,8-tetraidro-1,8-naftiridin-2-il)etil)pirrolidin-1-il)-3-(3-(2-metoxietoxi) fenil) butanoico

Info

Publication number
BR112018068877A2
BR112018068877A2 BR112018068877A BR112018068877A BR112018068877A2 BR 112018068877 A2 BR112018068877 A2 BR 112018068877A2 BR 112018068877 A BR112018068877 A BR 112018068877A BR 112018068877 A BR112018068877 A BR 112018068877A BR 112018068877 A2 BR112018068877 A2 BR 112018068877A2
Authority
BR
Brazil
Prior art keywords
naphthyridin
butanoic
methoxyethoxy
pyrrolidin
tetrahydro
Prior art date
Application number
BR112018068877A
Other languages
English (en)
Inventor
Saklatvala Paula
Jonathan Daniel Hatley Richard
John Fawcett Macdonald Simon
Yuen Eric Tse Sing
Barrett Tim
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of BR112018068877A2 publication Critical patent/BR112018068877A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

a invenção refere-se a um composto que seja sal de citrato (1:1) de ácido (s)-4-((s)-3-fluoro-3-(2-(5,6,7,8-tetraidro-1,8-naftiridin-2-il)etil)pirrolidin-1-il)-3-(3-(2-metoxietoxi) fenil) butanoico, composições farmacêuticas incluindo esse composto, e ao uso desse composto em terapia, incluindo no tratamento de uma doença ou afecção à qual um antagonista de avß6 integrina é indicado, e, em particular, fibrose pulmonar idiopática.
BR112018068877A 2016-03-18 2017-03-16 sal de citrato do composto de ácido (s)-4-((s)-3-fluoro-3-(2-(5,6,7,8-tetraidro-1,8-naftiridin-2-il)etil)pirrolidin-1-il)-3-(3-(2-metoxietoxi) fenil) butanoico BR112018068877A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1604589.0A GB201604589D0 (en) 2016-03-18 2016-03-18 Chemical compound
PCT/EP2017/056204 WO2017158072A1 (en) 2016-03-18 2017-03-16 Citrate salt of the compound (s)-4-((s)-3-fluoro-3-(2-(5,6,7,8-tetrahydro-1,8-naphthydrin-2-yl)ethyl)pyrrolidin-1-yl)-3-(3-(2-methoxyethoxy)phenyl) butanoic acid

Publications (1)

Publication Number Publication Date
BR112018068877A2 true BR112018068877A2 (pt) 2019-01-22

Family

ID=55968504

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018068877A BR112018068877A2 (pt) 2016-03-18 2017-03-16 sal de citrato do composto de ácido (s)-4-((s)-3-fluoro-3-(2-(5,6,7,8-tetraidro-1,8-naftiridin-2-il)etil)pirrolidin-1-il)-3-(3-(2-metoxietoxi) fenil) butanoico

Country Status (11)

Country Link
US (1) US20200291017A1 (pt)
EP (1) EP3430003A1 (pt)
JP (1) JP2019508475A (pt)
KR (1) KR20180127979A (pt)
CN (1) CN108699036A (pt)
AU (1) AU2017232285A1 (pt)
BR (1) BR112018068877A2 (pt)
CA (1) CA3017796A1 (pt)
GB (1) GB201604589D0 (pt)
RU (1) RU2018136580A (pt)
WO (1) WO2017158072A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
EP3589627A4 (en) 2017-02-28 2020-08-05 Morphic Therapeutic, Inc. INHIBITORS OF (ALPHA-V) (BETA-6) -INTEGRIN
PE20211640A1 (es) 2018-08-29 2021-08-24 Morphic Therapeutic Inc INHIBICION DE LA INTEGRINA xvß6

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003510360A (ja) * 1999-10-04 2003-03-18 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
GB201305668D0 (en) * 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
GB201417002D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound

Also Published As

Publication number Publication date
GB201604589D0 (en) 2016-05-04
KR20180127979A (ko) 2018-11-30
WO2017158072A1 (en) 2017-09-21
EP3430003A1 (en) 2019-01-23
CN108699036A (zh) 2018-10-23
US20200291017A1 (en) 2020-09-17
JP2019508475A (ja) 2019-03-28
CA3017796A1 (en) 2017-09-21
RU2018136580A (ru) 2020-04-20
AU2017232285A1 (en) 2018-08-02

Similar Documents

Publication Publication Date Title
BR112018068877A2 (pt) sal de citrato do composto de ácido (s)-4-((s)-3-fluoro-3-(2-(5,6,7,8-tetraidro-1,8-naftiridin-2-il)etil)pirrolidin-1-il)-3-(3-(2-metoxietoxi) fenil) butanoico
AR109452A1 (es) Formulación farmacéutica de un inhibidor de lsd1 y método de tratamiento
BR112018010018A2 (pt) moduladores de ror-gama
CY1126152T1 (el) Ενωσεις-αναστολεις της rip1 και μεθοδοι παρασκευης και χρησης αυτων
MA43518A (fr) 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase
MA40240A (fr) Composés hétéroaryle d'inhibition de la kinase
MA39753B1 (fr) Inhibiteurs de diacylglycérol acyltransférase pour le traitement de troubles métaboliques ou analogues
BR112018001534A2 (pt) inibidor de isocitrato desidrogenase idh1 r132h mutante
BR112014016643A2 (pt) estruturas fibrosas contendo ativo com múltiplas regiões tendo densidades diferentes
NO20092227L (no) Salter og krystallformer av 2-metyl-2-[4-(3-metyl-2-okso-8-konolin-3-yl-2,3-dihydro-imidazo[4,5-C]kinolin-1-yl)-fenyl]-propionitril
SG11201808607SA (en) Medicine obtained by combining fxr agonist and arb
BR112016015660A2 (pt) formulação farmacêutica de neuregulina (nrg) e formulação farmacêutica liofilizada de neuregulina (nrg)
BR112014014410A2 (pt) composições e métodos que compreendem uma variante de enzima lipolítica
MX2017014730A (es) Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3).
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
BR112013032711A2 (pt) composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase
BR112017016428A2 (pt) ?composto ou sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto ou sal farmaceuticamente aceitável, e, método para tratamento de um distúrbio hiperproliferativo maligno, de uma condição metabólica associada à obesidade, de um distúrbio autoimune ou de um distúrbio inflamatório?
WO2019236775A8 (en) Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
BR112018073951A2 (pt) forma cristalina inovadora de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida
BR112021026214A2 (pt) Método para tratamento de fibrose pulmonar idiopática
NZ732241A (en) A modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
BR112017025998A2 (pt) inibidor de eixo igfbp3/tmem219, composição farmacêutica para uso no tratamento e/ou prevenção de diabetes, método para identificar um indivíduo em risco de desenvolver diabetes tipo 1 e/ou tipo 2 ou para monitorar a resposta a um tratamento terapêutico em um indivíduo e kit
MA55799A (fr) Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2
BR112018013903A2 (pt) orvepitante para o tratamento de tosse crônica
BR112016029065A2 (pt) ?composto, composição farmacêutica, e, uso de um composto?

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]